Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has signed and dated the Informed Consent after the study had been fully explained.~2. Patient is male or female, at least 20 years of age when the Informed Consent is obtained.~3. American Society for Anesthesiologists (ASA) I to III Class.~4. Patient who requires sedation during the elective surgery which requires ≥30mins (expected time) without intubation under monitored sedation care.~5. Patient undergoing a surgery requiring epidural or spinal anesthesia~Exclusion Criteria:~1. Patient who underwent general anesthesia within 7 days, or who received other study drugs within 30 days from the date of consent.~2. Patient with \<92% SpO2, at the physical examination prior to the study drug administration, or ventilatory failure which requires intubation or Laryngeal Mask.~3. Patient with central nervous system pathology which may lead to increased intracranial pressure, uncontrolled seizures, psychiatric disorder which may be confused with the response to sedation treatment.~4. Patient who require general anesthesia.~5. Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven days of scheduled surgery or procedure.~6. Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used in the study are contraindicated.~7. Patient diagnosed with unstable angina or acute myocardiac infarction within 6 weeks from the date of consent.~8. Patient whose heart rate is \<60 bpm, systolic blood pressure is \<90 mmHg by the physical examination prior to the study drug administration.~9. Patient has third degree heart block, unless the patient has a pacemaker or transverse pacing wires are in place.~10. Patient who has experienced an increase in alanine transaminase (ALT) and / or aspartate aminotransferase (AST) more than double the upper normal limit within 2 months of the date of consent, or who has a history of liver insufficiency.~11. Pregnant or lactating woman.~12. In the Investigator's or subinvestigator's opinion, the patient has any symptom or condition which might increase risk to the patient by conducting the study or preclude obtaining satisfactory study data

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
- Dexmedetomidine 0.067 mcg/kg (Type: EXPERIMENTAL): Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
- Dexmedetomidine 0.25 mcg/kg (Type: EXPERIMENTAL): Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
- Dexmedetomidine 0.5 mcg/kg (Type: EXPERIMENTAL): Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
- Dexmedetomidine 1.0 mcg/kg (Type: EXPERIMENTAL): Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose

Based on this trial design, predict the completion outcome and termination type (if applicable).